Identifying NASH in Patients With Diabetes

This activity is jointly provided by The Postgraduate Institute for Medicine and Integritas Communications.

This activity is supported by an unrestricted educational grant from Gilead Sciences, Inc.

This activity is to be held in conjunction with the American Diabetes Association’s 79th Scientific Sessions.

Dinner will be provided.

Register Now!

Go to https://www4.cmrreg.com/ada2019/ to register for our Corporate Symposium at the American Diabetes Association’s 79th Scientific Sessions. Or go to Assisted Registration (Blue Area) located on Level 1 of the West Building at the Moscone Center to check availability and register while in San Francisco.

If our Symposium is sold out, you may check at the door 15 minutes prior to the event to see if space has become available.

Target Audience

This activity is intended for endocrinologists, diabetologists, diabetes nurse specialists, and diabetes educators engaged in the management of patients with diabetes who are at risk of nonalcoholic steatohepatitis (NASH).

Program Overview

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of potentially progressive liver disorders, ranging from simple hepatic steatosis to such severe forms as NASH and cirrhosis.¹ The prevalence of both NAFLD and NASH has been steadily trending upward for years, mirroring the rapid and well-documented expansions of patient populations with obesity and type 2 diabetes mellitus (T2DM).^2-4 More patients with T2DM have moderate to severe fibrosis, characteristic of NASH, than patients without T2DM.⁵ Thus, endocrinologists and other clinicians with a focus on diabetes management are essential to accelerating the identification of patients with NASH. Importantly, however, appropriate diagnostic and management approaches for patients with T2DM who have advanced fibrosis markedly differ from those for patients who have received an NAFLD diagnosis, and best-practice strategies are quickly evolving.⁶ Without any US Food and Drug Administration–approved treatments, lifestyle modification and antidiabetic therapies are the mainstay of treatment for NASH, though there are several ongoing clinical trials of therapies to treat NASH.⁷ During this Clinical Issues™ program, expert faculty will highlight epidemiologic and pathophysiologic relationships between NASH and T2DM, review clinical application of available noninvasive diagnostic and staging techniques, and discuss current and future management options.

References

1. Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181-205.
2. Hassan K, Bhalla V, El Regal ME, A-Kader HH. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol. 2014;20(34):12082-12101.
3. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133.
4. Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5):E774.
5. Koehler EM, Plompen EP, Schouten JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology. 2016;63(1):138-147.
6. Singh A, Lopez R, Le P, Alkhouri N. Prevalence of non-alchologic fatty liver disease and advanced fibrosis in type-2 diabetic patients via non-invasive methods. J Hepatol. 2017;66(suppl 1):S150.
7. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• ​Describe the epidemiology and interlinked pathophysiology of NASH and diabetes
• Utilize available noninvasive assessment tools for screening and diagnosis of NASH in patients with diabetes
• Evaluate the benefits and limitations of lifestyle modification and available antidiabetic therapies in patients with diabetes and NASH

Program Agenda

7:00 PM - 7:05 PM: Introductions and Preactivity Questionnaire
                                 Juan Pablo Frias, MD, FACE
7:05 PM – 7:25 PM: Appreciating the Scope and Pathophysiological Complexity of the NASH Problem
                                 Brent Neuschwander-Tetri, MD
7:25 PM – 7:50 PM: Recognizing Patients at Highest Risk—What You Need to Know and DO Today
                                 Including Clinical Tools-in-Action Audience Participation
                                 Stephen A. Harrison, MD
7:50 PM – 8:15 PM: Practical NASH-Management Strategies
                                 Kenneth Cusi, MD, FACP, FACE
8:15 PM – 8:30 PM: Postactivity Questionnaire and Question & Answer Session
                                 Juan Pablo Frias, MD, FACE

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

California Board of Registered Nursing

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.5 contact hours.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Nora Eldasher prior to the live event at neldasher@integritasgrp.com.